6 August company Healthcare Royalty, which buys royalties on tradable and late-stage biopharmaceuticals, announced the decision to postpone the upcoming IPO. The company has applied for attraction 750 million dollars, releasing 46,9 million shares (33% secondary) at a price from 15 to 17 dollars.
According to representatives of Healthcare Royalty, the company is the leader in the number of transactions and the total cost of capital, invested with 2016 years in the acquisition of royalties from medium-sized companies. The company's portfolio includes 35 products in 12 therapeutic categories, including Shingrix, Krystexxa и Xpovio. Since the founding of the company in 2006 year Healthcare Royalty has invested about 4,7 billion dollars in 76 royalties acquisition transactions 79 products.
Company headquartered in Stamford, Connecticut, was founded in 2006 year, and for 12 months, ended 31 Martha 2021 of the year, its revenue was 263 million dollars. The company planned to list on the exchange NYSE under the ticker HCRX. Goldman Sachs were to become the joint organizers of the share issue, Citi, Swiss credit, Jefferies, Cowen, SVB Leerink, Truist Securities, BMO Capital Markets, Stifel и Raymond James.